WEIGHT: 59 kg
Services: Sex anal, Facials, Cunnilingus, French Kissing, Rimming (receiving)
Larotrectinib is a selective TRK inhibitor approved by the FDA in for the treatment of any TRK fusion cancer based on a primary analysis in 55 patients from 3 clinical trials [Drilon et al. NEJM ]. Data cut-off was 19 February In the primary cohort of 55 patients with a median follow-up of 26 months, the median DOR in 44 patients with complete or partial responses was The median PFS in the primary cohort was Only one patient discontinued due to an AE related to larotrectinib.
These data confirm the marked tissue-agnostic efficacy and long durability of response in patients with TRK fusion cancer treated with larotrectinib. Larotrectinib continued to demonstrate a favorable long-term safety profile. Screening patients for NTRK gene fusions should be actively considered.
All other authors have declared no conflicts of interest. Oxford University Press is a department of the University of Oxford. It furthers the University's objective of excellence in research, scholarship, and education by publishing worldwide.
Sign In or Create an Account. Sign In. Advanced Search. Article Navigation. Close mobile search navigation Article Navigation. Volume Article Contents. Oxford Academic. Google Scholar. C M van Tilburg. C M Albert. B Geoerger. A F Farago. T W Laetsch. S Kummar. F Doz. U N Lassen.
Deptartment of Oncology, Rigshospitalet, Copenhagen, Denmark. S G DuBois. R McDermott. Medical Oncology, St. L Mascarenhas. J D Berlin. E R Rudzinski. M C Cox. Clinical Development, Loxo Oncology, Inc. S Nanda. B H Childs. A Drilon. D S Hong. Cite Citation. Permissions Icon Permissions.